Author: digi

Common Weaknesses in CRO CAPA Systems and How to Fix Them

August 17, 2025

Common Weaknesses in CRO CAPA Systems and How to Fix Them Addressing Weaknesses in CRO CAPA Systems for Stronger Compliance Introduction: Why CAPA Systems Are Under Scrutiny Corrective and Preventive Action (CAPA) systems are central to the compliance framework of Contract Research Organizations (CROs). Sponsor audits and regulatory inspections consistently evaluate CAPA systems to determine…

CAPA Management in CROs, CRO Audits, CAPA, and Deviation Management

Tracking KRIs for Protocol Compliance

August 17, 2025

digi

Tracking KRIs for Protocol Compliance How to Use KRIs to Monitor Protocol Compliance in Clinical Trials The Importance of Protocol Compliance in RBM Protocol compliance is a cornerstone of data integrity and patient safety in clinical trials. Deviations from the protocol can lead to invalid outcomes, regulatory scrutiny, or even trial suspension. With the rise…

Key Risk Indicators (KRIs), Risk-Based Monitoring (RBM)

Key Differences Between CTA and IND Submissions

August 17, 2025

digi

Key Differences Between CTA and IND Submissions CTA vs IND: Understanding the Key Differences in Clinical Trial Submissions Introduction: Why Compare CTA and IND? Clinical trial sponsors conducting studies across multiple regions often face the challenge of navigating distinct regulatory frameworks. In the United States, initiating a clinical trial requires filing an Investigational New Drug…

CTA (Clinical Trial Application), Regulatory Submissions and Approvals

Investigator Oversight Deficiencies in Clinical Trial Audit Reports

August 17, 2025

digi

Investigator Oversight Deficiencies in Clinical Trial Audit Reports Investigator Oversight Deficiencies in Clinical Trial Audit Reports Introduction: The Critical Role of Investigator Oversight Principal Investigators (PIs) hold ultimate responsibility for the conduct of clinical trials at their sites. Regulatory agencies such as the FDA, EMA, and MHRA consistently identify inadequate investigator oversight as a major…

Investigator Site-Level Audit Findings, Regulatory Audit Findings

Decentralized Clinical Trials: Lessons from Recent Implementations

August 17, 2025

digi

Decentralized Clinical Trials: Lessons from Recent Implementations Decentralized Clinical Trials: Implementation Lessons and Regulatory Oversight Introduction: The Rise of Decentralized Clinical Trials Decentralized Clinical Trials (DCTs) leverage digital technologies, telemedicine, and direct-to-patient logistics to reduce reliance on traditional site-based models. For US sponsors, the FDA encourages decentralized elements where appropriate, particularly under the 2020 FDA…

Clinical Trial Operations & Compliance, Clinical Trial Phases & Design

GPP Guidelines for Publication Ethics in Trials

August 17, 2025

digi

GPP Guidelines for Publication Ethics in Trials Ensuring Ethical Publication of Clinical Trials Through GPP Guidelines Introduction to GPP: Why Ethical Publication Matters Clinical trial publications shape medical guidelines, regulatory decisions, and patient care. Ethical lapses such as ghostwriting, selective reporting, or sponsor bias can undermine the scientific integrity of published results. To address these…

Clinical Trial Transparency and Ethics, Result Publication Requirements

Integrating Blockchain with EDC and CTMS Systems

August 17, 2025

digi

Integrating Blockchain with EDC and CTMS Systems How to Integrate Blockchain into Your Clinical EDC and CTMS Systems Introduction: Why Integrate Blockchain with EDC and CTMS? As clinical trial data volumes surge and regulatory expectations around traceability tighten, sponsors and CROs are exploring blockchain as a security and integrity solution. Integration of blockchain with traditional…

AI, Big Data, and Technology in Clinical Trials, Blockchain for Data Security

Archiving Superseded Protocol Versions Securely

August 17, 2025

digi

Archiving Superseded Protocol Versions Securely Securely Archiving Superseded Protocol Versions in Clinical Trials Why Secure Archiving of Protocol Versions Matters In clinical trials, the protocol serves as the central blueprint for study conduct. As amendments are introduced, older versions must be archived securely to preserve data integrity, ensure traceability, and meet regulatory expectations. Improper or…

Protocol Amendments and Version Control, Version Control Systems

Transparency in Reporting Rare Disease Trial Outcomes: Ethical and Regulatory Imperatives

August 17, 2025

digi

Transparency in Reporting Rare Disease Trial Outcomes: Ethical and Regulatory Imperatives Ensuring Transparency in Rare Disease Clinical Trial Reporting Why Transparency Matters in Rare Disease Trials In rare disease research, every datapoint matters. Due to the small patient populations, heterogeneous outcomes, and complex endpoints, publishing accurate and timely trial results becomes not just a regulatory…

Ethics & Patient Engagement, Rare and Orphan Disease Trials

Defining Clinical Endpoints in Cancer Vaccine Trials

August 17, 2025

digi

Defining Clinical Endpoints in Cancer Vaccine Trials Establishing Effective Clinical Endpoints for Cancer Vaccine Trials Introduction to Clinical Endpoints in Cancer Vaccine Development Clinical endpoints are measurable outcomes used to assess the efficacy, safety, and overall impact of a cancer vaccine in clinical trials. In oncology, defining the right endpoints is particularly challenging because cancer…

Cancer Vaccines, Oncology Clinical Trials